Welcome to our dedicated page for IM Cannabis SEC filings (Ticker: IMCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IM Cannabis Corp. filings document a foreign private issuer reporting on Form 6-K, with disclosures centered on its medical cannabis operations in Israel and Germany, material agreements, capital structure and governance. Recent reports cover convertible note and warrant financings, common share conversion terms, registration-statement incorporation by reference, Nasdaq minimum bid price compliance, and executive officer changes.
IMCC regulatory filings also include shareholder-meeting notices, board and management matters, risk-factor and regulatory disclosures, and operating or financial-result updates. The filings describe how financing instruments, common shares, warrants, listing requirements and governance actions affect the company’s public-company reporting framework.
IM Cannabis Corp. (IMCC) completed a private placement on September 2, 2026, issuing a US$225,000 convertible note and a warrant to an institutional investor. The company received US$202,500 in net proceeds, which it intends to use for general corporate purposes. The note carries 8.0% annual interest, rising to 14.0% upon an event of default, and is not repayable in cash; obligations are satisfied solely through issuance of common shares upon conversion.
The conversion price is the lower of a fixed price of US$3.328 per share or 90% of the lowest daily volume-weighted average price over the 20 trading days before conversion, subject to a floor price of US$0.665692, and is capped by a 4.99% beneficial ownership limit. The accompanying warrant permits purchase of up to 77,855 common shares at an exercise price of C$4.63 per share, is immediately exercisable, and expires on September 2, 2031. IM Cannabis agreed to reserve sufficient shares and to file a resale registration statement on Form F-3 with the SEC within specified timeframes.
IM Cannabis Corp. (IMCC) implemented a share consolidation, with its common shares beginning trading on a 30:1 post-consolidated basis on the Nasdaq Capital Market on August 27, 2026. The trading symbol IMCC is unchanged, but the CUSIP and ISIN have been updated to 44969Q505 and CA44969Q5059, respectively.
After the consolidation, the company’s common shares outstanding decreased from 18,567,650 to 618,899, with fractional shares rounded up at one-half or greater and otherwise cancelled. Exercise and conversion terms for all outstanding convertible securities were proportionately adjusted. Registered shareholders must exchange certificates via a mailed letter of transmittal, while beneficial holders will be processed automatically through their intermediaries.
IM Cannabis Corp. (IMCC) plans a 30-for-1 consolidation of its common shares, with one post-consolidation share for every thirty pre-consolidation shares, to support compliance with Nasdaq’s US$1.00 minimum bid price requirement. The board authorized the consolidation to be effected on or before September 15, 2026, and the company currently expects an effective date of August 27, 2026, when trading on a post-consolidation basis is anticipated to begin on Nasdaq, subject to final confirmations and implementation steps.
Following the consolidation, issued and outstanding common shares are expected to decrease from 18,117,650 to approximately 603,922 shares, with no fractional shares issued and rounding applied. The CUSIP and ISIN will change to 44969Q505 and CA44969Q5059, respectively, while the company name and ticker “IMCC” remain unchanged. IM Cannabis has until October 6, 2026 to regain compliance with Nasdaq’s minimum bid price rule and notes there is no assurance the consolidation will result in sustained compliance or continued listing.
IM Cannabis Corp. agreed to sell all shares of its subsidiary I.M.C. Holdings Ltd., which will hold the Company’s European-focused assets, to Slil.com Holding Ltd. under a definitive Share Purchase Agreement. Before closing, Israeli operations will be transferred out of IMC Holdings back to IM Cannabis or a wholly owned subsidiary, and approximately C$10,000,000 of intercompany indebtedness from IMC Holdings to IM Cannabis will be repaid as a capital contribution.
Consideration consists of acknowledgment of prior C$3,000,000 advance payments from Slil and Slil’s assumption of certain liabilities of IMC Holdings, which shall not materially exceed C$9,400,000 in aggregate, with no IM Cannabis securities issued. Management expects the Transactions to improve shareholders’ equity by about C$3.0 million, reduce debt, streamline the corporate structure, improve working capital and cash flow, and allow a focus on Israeli medical cannabis operations. Pro forma as of June 30, 2026, total liabilities decline from C$30.3 million to C$16.0 million and shareholders’ deficit narrows from C$5.6 million to C$2.6 million. Closing is subject to customary conditions and must occur by September 30, 2026, or the agreement may be terminated. The deal is a related party transaction under MI 61-101, and the company intends to rely on financial hardship exemptions.
IM Cannabis Corp. reported H1 2026 revenue of $16,268 thousand, down from $25,196 thousand a year earlier, and a net loss of $6,852 thousand. Q2 2026 revenue was $7,589 thousand with a net loss of $4,385 thousand. Revenue was split between Israel $7,313 thousand and Germany $8,955 thousand.
The balance sheet shows total assets of $24,692 thousand and total liabilities of $30,321 thousand, resulting in a shareholders’ deficit of $5,539 thousand. Cash was $1,617 thousand against bank and other credit of $12,065 thousand and a working capital deficit of $13,062 thousand. Management states that these conditions raise significant doubt about the Company’s ability to continue as a going concern.
The Company is relying on cost-saving measures, additional debt and equity financings, and growth in medical cannabis sales in Israel and Germany, including through several convertible promissory notes and warrant offerings. It also signed a non-binding letter of intent to transfer its European-focused assets to Slil.com Holding Ltd. in exchange for Slil assuming approximately $10.5 million of liabilities. The shares remain listed on Nasdaq but are currently below the minimum bid price requirement.
IM Cannabis Corp. entered into a private placement with an institutional investor, issuing a US$250,000 principal convertible note and a warrant for up to 2,052,545 common shares. After a 10% original-issue discount, the company received net proceeds of US$225,000 for general corporate purposes.
The note bears 8.0% annual interest, rising to 14.0% on default, and is repayable only in common shares. The conversion price is the lower of a fixed US$0.122 or 90% of the lowest 20-day VWAP, subject to a US$0.02436 floor and a 4.99% beneficial ownership cap. The warrant is immediately exercisable at C$0.17 per share until August 7, 2031. IM Cannabis agreed to reserve sufficient shares and file a Form F-3 resale registration within 30 trading days, targeting SEC effectiveness within agreed 60/90-day timelines.
IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, reports that director Alon Dayan resigned from the board effective July 26, 2026. His resignation is described as for personal reasons and not related to any disagreement over the company’s operations, policies or practices.
The company also issued a corporate update describing its medical cannabis platform, including import, distribution and retail pharmacy activities in Israel and distribution to pharmacies in Germany, and notes that it is evaluating opportunities to expand into additional technology-driven sectors, subject to regulatory, licensing and market risks highlighted in its cautionary forward-looking statements.
IM Cannabis Corp. completed a US$225,000 convertible note financing with an institutional investor on July 1, 2026. The note carries an 8% annual interest rate, rising to 14% upon an event of default, and is repayable only in common shares through conversion.
The conversion price is the lower of a fixed US$0.152 per share or 90% of the lowest daily volume-weighted average price over the 20 trading days before conversion, subject to a US$0.0303 floor. The company also issued a warrant to purchase up to 1,483,386 common shares at C$0.22 per share, exercisable immediately for five years.
IM Cannabis received net proceeds of US$202,500, which it intends to use for general corporate purposes. The note has a 4.99% beneficial ownership cap, and the company agreed to reserve sufficient shares and file a Form F-3 resale registration statement for the note and warrant shares within agreed timelines.
IM Cannabis Corp. has entered a non-binding letter of intent to sell its European-focused assets to Slil.com Holding Ltd., a private entity beneficially owned and controlled by CEO Oren Shuster. Slil would acquire IMC Holdings, which will primarily hold the Company’s European operations after a pre-closing reorganization.
In return, Slil is expected to assume approximately C$10,500,000 of debt, including C$7,500,000 in retained liabilities and C$3,000,000 in certain short-term liabilities, which the Company believes would significantly reduce its debt burden and improve working capital and cash flow. IMC would retain its core Israeli operations and focus on that market. The deal is a related party transaction under MI 61-101; a special independent committee and an external financial consultant have been engaged, and the Company intends to rely on “Financial Hardship” exemptions, with completion subject to a definitive agreement and other customary conditions.